INDV
NASDAQ
$39.12
Indivior Plc (INDV)
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Sector:
Healthcare
Strong Buy
Target: $50.83 (+29.93%)
Market Cap
$5.08B
Profit Margin
28.1%
Forward P/E
13.28
P/E Ratio
25.96
Price Chart
Valuation
Market Cap$5.08B
P/E25.96
Forward P/E13.28
P/S3.75
P/B145.25
Profitability
Total Revenue (TTM)$1.29B
Gross Profit (TTM)$1.10B
EBITDA$342M
Profit Margin28.1%
Operating Margin43.2%
EPS$1.58
Financial Health
Debt-to-Equity-337.5%
Free Cash Flow Yield-3.78%
Growth & Risk
Beta (5Y)0.71
Sharpe Ratio2.34